Damicava 600 mg/50 mg/300 mg Film-coated tablets
PDF Leaflet Revision Date: 22 March 2024
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of HIV infection in adults and adolescents.
Dosage (summary)
One tablet daily for adults and adolescents weighing at least 40 kg.
Onset of Action / Duration
Onset: 6 weeks, Duration: variable.
Special Populations
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Use during pregnancy may increase risk of neural tube defects; not recommended for breastfeeding.
Key Drug Interactions
- Metformin
- Rifampicin
- Antacids containing polyvalent cations
Contraindications
- Hypersensitivity to components
- Moderate to severe hepatic impairment
- Creatinine clearance < 50 mL/min
Common side effects
- Hypersensitivity reactions
- Nausea
- Diarrhoea
- Fatigue
- Rash
Counselling Points
- Inform about hypersensitivity risks
- Never restart after hypersensitivity
- Contact doctor if symptoms develop
Serious warnings
- Severe hypersensitivity reactions
- Lactic acidosis
- Pancreatitis
Important Disclaimer
The Damicava 600 mg/50 mg/300 mg Film-coated tablets professional information leaflet below is the property of Cipla Medpro Manufacturing and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
